Expert Discussion on Safety Results of Guselkumab for Crohn’s Disease
Panelists discuss how guselkumab demonstrated a very reassuring safety profile with no new safety signals or unexpected adverse events compared with placebo and consistent with safety data from other disease indications.
The safety evaluation of guselkumab in the GALAXI-2 and GALAXI-3 studies revealed a highly reassuring profile with no new safety signals or unexpected adverse events beyond those previously observed in other disease indications.
Uncontrolled disease itself represents the biggest safety concern.
The safety data demonstrated no meaningful differentiation from placebo across most adverse event categories, providing strong clinical confidence in the therapy’s tolerability.
Guselkumab requires no different monitoring protocols than standard care for Crohn’s disease patients on advanced therapies.
Author’s summary: Guselkumab shows a reassuring safety profile for Crohn’s disease.
More News
- Don Was and The Pan-Detroit Ensemble tour debut album - C-VILLE Weekly
- How accurate are the flood-risk ratings behind home insurance premium hikes? | CHOICE
- Bulawayo town clerk digs in over exit
- Bulawayo water crisis a cause of concern
- ACLU Attorney Reflects on Texas Death Penalty Case
- Welsh Government revives £100m Llandeilo bypass plan
- Africa’s Best Energy Choice Is Geothermal
- Tesla’s FSD Might Be 200 Times Safer Than Human Drivers, Even as NHTSA Opens a New Safety Investigation
- Gaffney girls tennis sweep Boiling Springs, Wade Hampton - The Gaffney Ledger
- United Way of Delta County focuses on school readiness